Crispr Therapeutics (CRSP) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Crispr Therapeutics (NASDAQ:CRSP) from a hold rating to a sell rating in a research report report published on Thursday.

According to Zacks, “CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. “

Several other analysts also recently commented on CRSP. Cann reiterated a hold rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. SunTrust Banks restated a hold rating and set a $16.00 price target on shares of Crispr Therapeutics in a research report on Friday, November 10th. BidaskClub lowered shares of Crispr Therapeutics from a buy rating to a hold rating in a research report on Saturday, December 2nd. Oppenheimer initiated coverage on shares of Crispr Therapeutics in a research report on Thursday, December 7th. They set a hold rating for the company. Finally, Piper Jaffray Companies initiated coverage on shares of Crispr Therapeutics in a research report on Friday, December 22nd. They set an overweight rating for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $22.81.

Shares of Crispr Therapeutics (NASDAQ:CRSP) opened at $39.45 on Thursday. The company has a market cap of $1,770.00 and a PE ratio of -123.28. Crispr Therapeutics has a 1-year low of $11.63 and a 1-year high of $42.90.

Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). The firm had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The business’s revenue for the quarter was up 54.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.77) EPS. analysts expect that Crispr Therapeutics will post -2.42 earnings per share for the current fiscal year.

In related news, insider Tyler Dylan-Hyde sold 66,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $28.03, for a total transaction of $1,849,980.00. Following the completion of the transaction, the insider now owns 25,204 shares in the company, valued at $706,468.12. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Thomas Woiwode sold 1,700 shares of the stock in a transaction dated Friday, November 24th. The shares were sold at an average price of $20.21, for a total transaction of $34,357.00. Following the transaction, the director now owns 8,218 shares of the company’s stock, valued at approximately $166,085.78. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,234,504 shares of company stock valued at $44,388,553. 39.98% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new position in Crispr Therapeutics during the third quarter valued at about $536,000. Hershey Trust Co. bought a new position in Crispr Therapeutics during the third quarter valued at about $768,000. Tiff Advisory Services Inc. bought a new position in Crispr Therapeutics during the third quarter worth about $505,000. Allianz Asset Management GmbH bought a new position in Crispr Therapeutics during the third quarter worth about $2,384,000. Finally, Granahan Investment Management Inc. MA boosted its position in Crispr Therapeutics by 51.7% during the third quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock worth $4,713,000 after purchasing an additional 89,839 shares during the period. Institutional investors own 22.02% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Crispr Therapeutics (CRSP) Rating Lowered to Sell at Zacks Investment Research” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.com-unik.info/2018/01/28/crispr-therapeutics-crsp-rating-lowered-to-sell-at-zacks-investment-research.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit